Marketing on a Budget: An Internet Launch

LAM. Pharmaceutical Corp., a tiny firm hoping to compete in the highly fragmented wound-healing market, has hired RxCentric to help it launch its new hyaluronic gel via the Internet. L.A.M. is betting that the approach can effectively but relatively inexpensively showcase a product that management believes is clinically superior to the offerings of much larger companies.

Like many small companies, LAM Pharmaceutical Corp. was founded on the belief that it could inexpensively commercialize a product that would prove clinically superior to competing offerings of major drugmakers. So far, so good. The eight-year-old, ten-person firm recently won FDA's clearance to begin marketing its first product—a proprietary gel formulation of hyaluronic acid (HA) that management figures has taken $15 million to develop. HA is a natural substance known to be a major component in the interstitial fluid between cells.

LAM believes that its LAM IPM Wound Gel will yield consistently good healing results, largely because of the formulation technology behind it. The gel contains a 2.5% concentration of sodium...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By 

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.